Mode
Text Size
Log in / Sign up

Meta-analysis identifies 101 genetic risk loci including 12 novel sites for systemic lupus erythematosusGenetic study finds 12 new lupus risk genes

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note the identification of 101 risk loci and 2,209 likely causal genes to inform future drug target discovery.

This meta-analysis analyzed a large cohort of 22,494 cases with systemic lupus erythematosus (SLE) and 1,568,102 healthy controls to identify genetic risk loci. The analysis identified 101 risk loci for SLE, which included 12 novel loci. Within these loci, the study identified 2,209 likely causal genes, from which 265 were prioritized for further investigation.

The study reported a liability scale of the heritability of SLE at 25.49%. Additionally, the analysis found positive genetic correlations between SLE and rheumatoid arthritis, schizophrenia, and hypertension. These findings suggest potential pathways for identifying druggable targets and exploring drug repurposing possibilities.

While the identification of specific loci like BLK suggests potential therapeutic targets, these are currently only suggested by genetic association and not confirmed as clinical treatments. The study also highlights riboflavin as a candidate for drug repurposing based on the analysis. Clinical application remains preliminary as the results reflect genetic associations rather than direct evidence of treatment efficacy.

How this fits prior evidence

This meta-analysis addresses a gap in identifying specific genetic drivers for systemic lupus erythematosus. While prior coverage noted that medicinal and edible plants show potential immunomodulatory effects, this study provides a different avenue by identifying 101 risk loci and suggesting riboflavin as a candidate for drug repurposing based on genetic analysis.

A large genetic study looked at DNA from more than 22,000 people with lupus and over 1.5 million healthy controls. The goal was to find genetic changes that increase the risk of developing systemic lupus erythematosus (SLE), an autoimmune disease that can affect many parts of the body.

The researchers identified 101 risk locations in the genome, including 12 that were new. They also pointed to 2,209 likely causal genes, with 265 prioritized for further study. The heritability of lupus was estimated at about 25.49%, meaning genetics explains about a quarter of the risk.

The study found that lupus shares genetic links with other conditions, including rheumatoid arthritis, schizophrenia, and hypertension. This suggests some common biological pathways may be involved.

Because this is a meta-analysis, it combines results from many studies, which adds strength. However, the findings are associations, not proof that these genes cause lupus. The suggested drug targets, like BLK, and repurposing ideas, such as riboflavin, are early possibilities, not confirmed treatments.

For people with lupus or a family history, this research is a step toward better understanding the disease, but it does not change current care. Always talk to your doctor about your personal risk and treatment options.

What this means for you:
New genetic clues may guide future lupus treatments, but they are not ready for clinical use.

Common questions

What did the study find about lupus and genetics?

The study identified 101 risk locations for lupus, including 12 new ones. It also pointed to 2,209 likely causal genes, with 265 prioritized. This means genetics plays a role in about 25.49% of lupus risk.

Does this mean a new lupus treatment is available?

No. The study suggests potential targets, like the BLK gene, and possible drug repurposing, such as riboflavin. But these are early ideas, not proven treatments. More research is needed before any new therapy is available.

Who was included in the study?

The study included 22,494 people with lupus and 1,568,102 healthy controls. They were from multiple ancestries, which helps make the findings more generalizable.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
Systemic lupus erythematosus (SLE) is a chronic life-threatening and relapsing-remitting multisystem autoimmune disease. However, the genetic susceptibility of SLE has not been fully elucidated. This study will explore the genetic risk loci of SLE. We performed the larger multi-ancestry meta-analysis of genome-wide association study (GWAS) including 22,494 cases with SLE and 1,568,102 healthy controls. Multi-ancestry meta-analysis identified 101 risk loci including 12 novel loci. Across 101 loci, 2,209 likely causal genes are indicated and 265 genes are prioritized, based on eight biological prioritization criteria. The most significantly locus were located on 6p21.32, whereas the highest-ranked candidate causal gene was BLK. Heritability analyses demonstrated a liability scale of the heritability is 25.49%, whereas an estimated 1.25 million effective sample sizes would be necessary to explain 90% of phenotypic variance. Gene enrichment, gene-set analyses, and the genetic correlation revealed that SLE-related genes were enriched in whole blood and spleen, promoted MHCII-related pathways, JAK-STAT signaling, abnormal activation of T and B cells, autoantibodies such as anti-nuclear antibody and anti-neutrophil antibody production, and had a positive genetic correlation with autoimmune diseases (e.g., rheumatoid arthritis), mental and neurological disorders (e.g., schizophrenia), and cardiovascular diseases (e.g., hypertension). Finally, druggable, gene-drug interaction, drug target, and drug repurposing analysis suggested some potential targets (e.g., BLK) and drug (e.g., riboflavin) repurposing for SLE. In conclusion, we identified 101 risk loci including 12 novel loci for SLE. Based on 101 loci, we provided new biological insights, some potential targets, and drug repurposing for SLE.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.